With this contracting file whose conditions are established in the specifications, it is intended to cover the use of the medicine included in the file to meet the clinical needs of Osakidetza patients and related centers and which are summarized in the report's memory.
Active substance: Bendamustine (DOE).
Amount of active substance: 25 and 100 mg.
Pharmaceutical form: vial.
Packaging conditions: unit dose.
Maximum price: EUR 22.59 / 25 mg vial and EUR 90.36 / 100 mg vial (Taxes not included).
Number of units planned: 1 200 25 mg vials and 1 350 100 mg vials (First year of contract).
Maximum estimated budget: 149 094.00 EUR (First year of contract).
Active substance: Teicoplanin (DOE).
Amount of active substance: 200 and 400 mg.
Pharmaceutical form: vial.
Packaging conditions: unit dose.
Maximum price: EUR 4.30 / 200 mg vial and EUR 8.60 / 400 mg vial (Tax not included).
Number of units planned: 300 vials of 200 mg and 6 000 vials of 400 mg (First year of contract).
Maximum estimated budget: 52,890.00 EUR (First year of contract).
Active substance: Omeprazole (DOE).
Amount of active substance: 20 mg.
Pharmaceutical form: capsule.
Packaging conditions: unit dose.
Maximum price: EUR 2.70 / 100 capsules (Taxes not included).
Number of units planned: 750,000 capsules (First year of contract).
Maximum estimated budget: EUR 20 250.00 (First year of contract).
Active substance: Cefazolin (DOE).
Amount of active substance: 1 g and 2 g.
Pharmaceutical form: vial.
Packaging conditions: unit dose.
Maximum price: EUR 47.00 / 100 vials of 1 g and 96.00 EUR / 100 vials of 2 g (Taxes not included).
Number of units planned: 80,000 vials of 1 g intravenously and 38,000 vials of 2 g intravenous (First year of contract).
Maximum estimated budget: 74 080.00 EUR (First year of contract).
Active substance: Entecavir (DOE).
Amount of active substance: 0.5 mg and 1 mg.
Pharmaceutical form: tablet.
Packaging conditions: unit dose preferably.
Maximum price: EUR 0.91 / 0.5 mg tablet and 0.94 EUR / 1 mg tablet (Taxes not included).
Number of units planned: 90,000 tablets of 0.5 and 17,000 tablets of 1 mg (First year of contract).
Estimated maximum budget: EUR 97 880.00 (First year of contract).